{"title":"味之素收购Althea Technologies扩大生物制剂开发和制造能力","authors":"Heather Cartwright","doi":"10.3833/pdr.v2013i4.1913","DOIUrl":null,"url":null,"abstract":"Ajinomoto has agreed to acquire Althea Technologies, a US-based provider of biopharmaceutical development and manufacturing services, in a deal valued at approximately US$175 M. The Japanese company has been manufacturing amino acids for more than 100 years and in recent years has been offering contract process development for biopharmaceuticals. Althea’s formulation technology platform includes Crystalomics®, a proprietary technology that provides a means of formulating large molecules that must be delivered at high concentrations or as sustained-release formulations.","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"72 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2013-01-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Ajinomoto Expands Biologics Development and Manufacturing Capabilities with Althea Technologies Purchase\",\"authors\":\"Heather Cartwright\",\"doi\":\"10.3833/pdr.v2013i4.1913\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Ajinomoto has agreed to acquire Althea Technologies, a US-based provider of biopharmaceutical development and manufacturing services, in a deal valued at approximately US$175 M. The Japanese company has been manufacturing amino acids for more than 100 years and in recent years has been offering contract process development for biopharmaceuticals. Althea’s formulation technology platform includes Crystalomics®, a proprietary technology that provides a means of formulating large molecules that must be delivered at high concentrations or as sustained-release formulations.\",\"PeriodicalId\":19951,\"journal\":{\"name\":\"Pharmadeals Review\",\"volume\":\"72 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2013-01-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pharmadeals Review\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3833/pdr.v2013i4.1913\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmadeals Review","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3833/pdr.v2013i4.1913","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Ajinomoto Expands Biologics Development and Manufacturing Capabilities with Althea Technologies Purchase
Ajinomoto has agreed to acquire Althea Technologies, a US-based provider of biopharmaceutical development and manufacturing services, in a deal valued at approximately US$175 M. The Japanese company has been manufacturing amino acids for more than 100 years and in recent years has been offering contract process development for biopharmaceuticals. Althea’s formulation technology platform includes Crystalomics®, a proprietary technology that provides a means of formulating large molecules that must be delivered at high concentrations or as sustained-release formulations.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
